Indigo is a EC Horizon 2020 project in partnership with India’s Department of Biotechnology
Luuk Hilgers has more than 30 years of experience in vaccine research in established industry and bio-pharmaceutical start-ups. He pioneered synthetic molecules as immunomodulators and one of his inventions is exploited worldwide as adjuvant in single-shot vaccines for veterinary purposes. He co-founded LiteVax B.V. (previously CoVaccine B.V.) and co-developed CoVaccine HT and LiteVax Adjuvant for human therapeutic and prophylactic vaccines. He gained ample experience in turning innovative ideas into successful concepts and business and received several EU grants. He is passionate about complex scientific challenges and inspiring collaborations.